Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 10/20 | 0.47 |
| ▸ | AR | P10275 | 10/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.37 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.37 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10355913 | 0.81 | PGR (0.46) | PGRARLMNAABCC4ABCB11 | |
| SCHEMBL13342051 | 0.81 | PGR (0.50) | PGRARLMNAABCC4ABCB11 | |
| SCHEMBL10355845 | 0.81 | PGR (0.50) | PGRARLMNAABCC4ABCB11 | |
| SCHEMBL10355848 | 0.80 | PGR (0.35) | PGRARNR3C1CHRM2 | |
| SCHEMBL12568121 | 0.79 | PGR (0.59) | PGRARLMNAABCC4ABCB11 | |
| SCHEMBL16852429 | 0.79 | PGR (0.59) | PGRARLMNAABCC4ABCB11 | |
| SCHEMBL16852318 | 0.79 | PGR (0.59) | PGRARLMNAABCC4ABCB11 | |
| SCHEMBL16852316 | 0.79 | PGR (0.59) | PGRARLMNAABCC4ABCB11 | |
| SCHEMBL10355962 | 0.78 | PGR (0.51) | PGRARLMNAABCC4ABCB11 | |
| SCHEMBL10355910 | 0.71 | PGR (0.49) | PGRARLMNAABCC4ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8222237-B2 | Progestational 3-(6,6-ethylene-17B-hydroxy-3-oxo-17A-pregna-4-ene-17A-yl)propionic acid G-lactones | EVESTRA, INC. (US) | 2012-07-17 | — | — | US | disclosed |
| US-20100137264-A1 | PROGESTATIONAL 3-(6,6-ETHYLENE-17B-HYDROXY-3-OXO-17A-PREGNA-4-ENE-17A-YL)PROPIONIC ACID G-LACTONES | EVESTRA, INC. | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137264-A1 | PROGESTATIONAL 3-(6,6-ETHYLENE-17B-HYDROXY-3-OXO-17A-PREGNA-4-ENE-17A-YL)PROPIONIC ACID G-LACTONES | HSD17B11, CYP17A1, NR3C2 | PGR 14/4885AR 53/4885LMNA 947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.